The socio-economical burden of schizophrenia: A simulation of cost-offset of early intervention program in Italy

European Psychiatry

Volumn 24, Issue 1, 2009, Pages 11-16

  Serretti, Alessandro ^a   Mandelli, Laura ^a   Bajo, Emanuele ^a   Cevenini, Nadia ^a   Papili, Pietro ^a   Mori, Elisa ^a   Bigelli, Marco ^a   Berardi, Domenico ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cost benefit; Pharmacoeconomics; Psychosocial interventions; Schizophrenia; Socio economic burden

Indexed keywords

ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; HEALTH CARE COST; HEALTH PROGRAM; HOSPITAL ADMISSION; ITALY; MENTAL HEALTH CARE; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA; SIMULATION; SOCIOECONOMICS;

COMBINED MODALITY THERAPY; COMMUNITY MENTAL HEALTH CENTERS; COST-BENEFIT ANALYSIS; DISABILITY EVALUATION; EARLY DIAGNOSIS; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; ITALY; MODELS, ECONOMIC; NATIONAL HEALTH PROGRAMS; PATIENT ADMISSION; QUALITY OF LIFE; RECURRENCE; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 58149115060     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2008.07.009     Document Type: Article

References (36)

1. Addington J., Leriger E., and Addington D. Symptom outcome 1 year after admission to an early psychosis program. Can J Psychiatry 48 3 (2003) 204-207
2. Amminger G.P., Harris M.G., Conus P., Lambert M., Elkins K.S., Yuen H.P., et al. Treated incidence of first-episode psychosis in the catchment area of EPPIC between 1997 and 2000. Acta Psychiatr Scand 114 5 (2006) 337-345
3. Andrews G., Sanderson K., Corry J., Issakidis C., and Lapsley H. Cost-effectiveness of current and optimal treatment for schizophrenia. Br J Psychiatry 183 (2003) 427-435 discussion 436
4. Arranz M.J., Collier D., and Kerwin R.W. Pharmacogenetics for the individualization of psychiatric treatment. Am J Pharmacogenomics 1 1 (2001) 3-10
5. Arranz M.J., Munro J., Birkett J., Bolonna A., Mancama D., Sodhi M., et al. Pharmacogenetic prediction of clozapine response. Lancet 355 9215 (2000) 1615-1616
6. Arranz M.J., Munro J., Osborne S., Collier D., and Kerwin R.W. Applications of pharmacogenetics in psychiatry: personalisation of treatment. Expert Opin Pharmacother 2 4 (2001) 537-542
7. Carbone S., Harrigan S., and McGorry P. Duration of untreated psychosis and 12-month outcome in first-episode psychosis: the impact of treatment approach. Acta Psychiatr Scand 100 (1999) 96-104
8. Davies L.M., and Drummond M.F. Economics and schizophrenia: the real cost. Br J Psychiatry Suppl 25 (1994) 18-21
9. Eccles M., and Mason J. How to develop cost-conscious guidelines. Health Technol Assess 5 16 (2001) 1-69
10. Haycox A. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models. Pharmacoeconomics 23 Suppl. 1 (2005) 3-16
11. Knapp M. Costs of schizophrenia. Br J Psychiatry 171 (1997) 509-518
12. Lauber C., Keller C., Eichenberger A., and Rossler W. Family burden during exacerbation of schizophrenia: quantification and determinants of additional costs. Int J Soc Psychiatry 51 3 (2005) 259-264
13. Lehman A.F. Improving treatment for persons with schizophrenia. Psychiatr Q 70 4 (1999) 259-272
14. Malhotra A.K., Murphy Jr. G.M., and Kennedy J.L. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161 5 (2004) 780-796
15. Malla A., Norman R., and Manchanda R. Symptoms, cognition, treatment adherence and functional outcome in first-episode psychosis. Psychol Med 32 (2002) 1109-1119
16. Malla A., Norman R., and McLean T. Impact of phase-specific treatment of first episode of psychosis on Wisconsin quality of life index (client version). Acta Psychiatr Scand 103 (2001) 355-361
17. Marshall M., and Rathbone J. Early intervention for psychosis. Cochrane Database Syst Rev 4 (2006) CD004718
18. McGlashan T.H. A selective review of recent North American long-term followup studies of schizophrenia. Schizophr Bull 14 4 (1988) 515-542
19. McGorry P.D. The nature of schizophrenia: signposts to prevention. Aust N Z J Psychiatry 34 Suppl (2000) S14-S21
20. McGorry P.D., Edwards J., Mihalopoulos C., Harrigan S.M., and Jackson H.J. EPPIC: an evolving system of early detection and optimal management. Schizophr Bull 22 2 (1996) 305-326
21. Mihalopoulos C., McGorry P.D., and Carter R.C. Is phase-specific, community-oriented treatment of early psychosis an economically viable method of improving outcome?. Acta Psychiatr Scand 100 1 (1999) 47-55
22. Mueser K., and McGurk S. Schizophrenia. Lancet 19 (2004) 2063-2072
23. Papili P., Cevenini N., Mori E., Rossi E., Mandelli L., Michetti R., et al. Early intervention in psychosis: pharmacological and psychosocial treatment. Minerva Psichiatr 48 2 (2007) 225-236
24. Percudani M., Barbui C., and Tansella M. Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia: an economic perspective. Pharmacoeconomics 22 11 (2004) 701-718
25. Polsky D., Doshi J.A., Bauer M.S., and Glick H.A. Clinical trial-based cost-effectiveness analyses of antipsychotic use. Am J Psychiatry 163 12 (2006) 2047-2056
26. Power P., Elkins K., and Adlard S. Analysis of the initial treatment phase in first-episode psychosis. Br J Psychiatry 172 Suppl. 33 (1998) 71-76
27. Rossler W., Salize H.J., van Os J., and Riecher-Rossler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 15 4 (2005) 399-409
28. Rouillon F., Toumi M., Dansette G.Y., Benyaya J., and Auquier P. Some aspects of the cost of schizophrenia in France. Pharmacoeconomics 11 6 (1997) 578-594
29. Salize H.J., and Rossler W. The cost of comprehensive care of people with schizophrenia living in the community. A cost evaluation from a German catchment area. Br J Psychiatry 169 1 (1996) 42-48
30. Segman R.H., Goltser T., Heresco-Levy U., Finkel B., Shalem R., Schlafman M., et al. Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia. Pharmacogenomics J 3 5 (2003) 277-283
31. Tarricone R., Gerzeli S., Montanelli R., Frattura L., Percudani M., and Racagni G. Direct and indirect costs of schizophrenia in community psychiatric services in Italy. The GISIES study. Interdisciplinary study group on the economic impact of schizophrenia. Health Policy 51 1 (2000) 1-18
32. Velligan D.I., Kern R.S., and Gold J.M. Cognitive rehabilitation for schizophrenia and the putative role of motivation and expectancies. Schizophr Bull 32 3 (2006) 474-485
33. Vos T., Haby M.M., Magnus A., Mihalopoulos C., Andrews G., and Carter R. Assessing cost-effectiveness in mental health: helping policy-makers prioritize and plan health services. Aust N Z J Psychiatry 39 8 (2005) 701-712
34. World Health Organization. Impact of disorders (2001). http://www.who.int/whr/2001/chapter2/en/index3.html
35. Zhang M., Wang M., Li J., and Phillips M.R. Randomised-control trial of family intervention for 78 first-episode male schizophrenic patients. An 18-month study in Suzhou, Jiangsu. Br J Psychiatry Suppl 24 (1994) 96-102
36. Zimbroff D.L., Allen M.H., Battaglia J., Citrome L., Fishkind A., Francis A., et al. Best clinical practice with ziprasidone IM: update after 2 years of experience. CNS Spectr 10 9 (2005) 1-15